Medpace (NASDAQ:MEDP) Director Sells $3,043,150.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Brian Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Price Performance

Shares of MEDP traded up $8.11 on Friday, reaching $620.75. The company’s stock had a trading volume of 225,439 shares, compared to its average volume of 347,887. The stock’s 50 day simple moving average is $547.09 and its two-hundred day simple moving average is $491.80. The stock has a market capitalization of $17.33 billion, a P/E ratio of 36.39, a PEG ratio of 2.71 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MEDP. BlackRock Inc. bought a new stake in Medpace during the second quarter valued at about $1,323,047,000. AQR Capital Management LLC raised its stake in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP lifted its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on Medpace in a research note on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.